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Edited by Robert BaroukiAbstract This study describes the molecular mechanism by
which treatment with 3-AB, a potent inhibitor of PARP, allows
human osteosarcoma MG-63 cells to restrict growth and enter
diﬀerentiation. Our ﬁndings show that in MG-63 cells, aberrant
gene expression keeps Rb protein constitutively inactivated
through hyperphosphorylation and this promotes uncontrolled
proliferation of the cells. After 3-AB-treatment, the poly(ADP-
ribosyl)ation of nuclear proteins markedly decreases and this re-
sults in an increase in both the hypophosphorylated active form
of Rb and pRb/E2F complexes. These eﬀects are accompanied
by G1 arrest, downregulation of gene products required for pro-
liferation (cyclin D1, b-catenin, c-Jun, c-Myc and Id2) and
upregulation of those implicated in the osteoblastic diﬀerentia-
tion (p21/Waf1, osteopontin, osteocalcin, type I collagen, N-
cadherins and alkaline phosphatase). Our study suggests that
use of PARP inhibitors may induce a remodeling of chromatin
with the reprogramming of gene expression and the activation
of diﬀerentiation.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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In eukaryotic cells, PARP catalyzes poly(ADP-ribosyl)ation
reactions, which transfer the poly(ADP-ribose) moiety to his-
tone and non-histone proteins [1]. It has been suggested that
PARP can be critical for gene regulation in vivo by creating
an anionic poly(ADPribose) matrix that binds histones, there-
by promoting the decondensation of higher-order chromatin
structures [2].
Accumulated data suggest that PARP takes part mainly in
nuclear events, including DNA repair, cell cycle [3], apoptosis
[4], and maintenance of chromosomal stability [5]. ActivationAbbreviations: PARP, poly(ADP-ribose)polymerase; 3-AB, 3-aminob-
enzamide
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as stroke, myocardial ischemia, diabetes and central nervous
system pathologies. Therefore, inhibition of PARP by pharma-
cological agents has been suggested as a useful treatment for
these diseases [6,7].
We have recently demonstrated [8] that in human osteosar-
coma cells, treatment with 3-aminobenzamide (3-AB), a potent
inhibitor of PARP, activates a conﬂicting signal which deter-
mines a diﬀerent ﬁnal destiny for cells that express functional
Rb protein from those that do not. In Saos-2 cells lacking
Rb function, 3-AB treatment drives cells through an apoptotic
pathway, while in MG-63 cells expressing wild-type Rb, 3-AB
treatment drives cells to diﬀerentiate into osteocyte-like cells.
Our aim in this study was to elucidate the molecular mecha-
nism by which PARP inhibition allows human osteosarcoma
MG-63 cells to restrict growth and enter diﬀerentiation. We
demonstrate for the ﬁrst time that inhibiting PARP in human
osteosarcoma MG-63 cells results in the activation of func-
tional Rb with downregulation of gene products required for
proliferation and upregulation of those required for diﬀerenti-
ation. These ﬁndings suggest that the reduction in ADP-
ribosylation of nuclear proteins induced by 3-AB treatment
may determine a modulation in chromatin structure which in
turn may result in a reprogramming of gene expression.2. Materials and methods
2.1. Cell culture and reagents
Human osteosarcoma MG-63 cells were routinely grown as previ-
ously described [8]. The cells were treated with either vehicle or 10
mM 3-AB for the times indicated in the Figures. Material for RT-
PCR was from Applied Biosystems (CA, USA). Anti-poly(ADP-ri-
bose) monoclonal antibody 10H was kindly supplied by Prof. Alexan-
der Bu¨rkle, University of New Castle upon Tyne UK; Phosphoplus Rb
(Ser-780, Ser-795, Ser-807/811) antibodies were from Cell Signaling
Technology; all other antibodies were from Santa Cruz Biotechnology,
Inc. Other materials and reagents were from Sigma–Aldrich.
2.2. Flow cytometry analysis
MG-63 cells were incubated in the absence or presence of 3-AB, har-
vested, centrifuged, resuspended in 400 ll of PBS containing 10 lg/ml
RNase, and stained with 50 lg/ml propidium iodide. Samples of 2–
4 · 105 cells were then analyzed for DNA histograms and cell cycle
phase distributions by ﬂow cytometer using a Coulter Epics XL (Beck-
man Coulter). To evaluate whether 3-AB-induced G-1 phase arrest was
reversible, after 48 h of 3-AB treatment the medium was removed, and
cells were washed and refed with fresh control medium without 3-AB.
After an additional 24, 48, or 72 h following the removal of 3-AB, cells
were analyzed for DNA histograms and cell cycle phase distributions.blished by Elsevier B.V. All rights reserved.
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10 · 106 cells were incubated in the absence or presence of 3-AB,
harvested and the nuclei were extracted as reported by Rabinovich
et al. [9].
2.4. Western blot analysis and immunoprecipitation
Whole cell lysates were obtained by disrupting cells in lysis buﬀer [8].
Equal amounts of proteins (60 lg) were separated by SDS–PAGE and
transferred onto nitrocellulose membranes. In each experiment, Pon-
ceau S staining was performed to check that closely comparable
amounts of proteins had been loaded and transferred in each lane.
The ﬁlters were then probed with the speciﬁc antibodies. Reprobing
was performed following incubation of membranes in stripping buﬀer
(100 mM b-mercaptoethanol, 2% SDS and 62.5 mM Tris–Cl, pH 6.7)
overnight. Bands were quantiﬁed by densitometric analysis [8]. For
immunoprecipitations, 400 lg of nuclear extracts was incubated with
0.4 lg of the appropriate primary antibody for 3 h and then incubated
overnight with 30 ll of protein A/G plus agarose beads. The immuno-
complexes were washed with lysis buﬀer, boiled in SDS sample buﬀer
and submitted to Western blotting.
2.5. RT-PCR analysis
RNA was isolated from MG-63 cells using RNeasy mini kit (Qia-
gen). cDNA was ampliﬁed from 1 lg of RNA and PCR was performed
as previously reported [8]. The ampliﬁed products were resolved by
agarose gel electrophoresis (1% agarose–0.5 lg/ml ethidium bromide)
and then photographed and scanned into Adobe Photoshop. GAPDH
was employed as an internal control. The following primer pairs
(Proligo USA) were used. b-catenin: 285 bp, 5 0-CGTGGACAATG-
GCTACTCAAGC-30 sense/ 5 0-TCTGAGCTCGAGTCATTGCA-
TAC-30 antisense; cyclin D1: 587 bp, 50-TGGATGCTGGAGGTCTG-
CGAGGAA-3 0 sense/5 0-GCTTGACTCCAGCAGGGCTTCGAT-3 0
antisense; GAPDH: 200 bp, 5 0-TGACATCAAGAAGGTGA-3
sense/5 0-TCCACCACCCTGTTGCTGTA-3 0 antisense; ID2: 207 bp,
5 0-CATCTTGGACCTGCAGATCG-3 0 sense/5 0-ATGAACACCGC
TTATTCAGC-3 0 antisense; c-Jun: 316 bp, 5 0-GGAAACGACCTTC-
TATGACG-3 0 sense/5 0-GAACCCCTCCTGCTCATCTGTCACGT
TCTT-3 0 antisense; c-Myc: 239 bp, 5 0-GACCACAAG GCCCTCAG-
TAC-3 0 sense/5 0-GTGGATGGGAAGGCATCGTT-3 0 antisense;
osteocalcin: 241 bp, 5 0-CTCACACTCCTCGCCCTATT-3 0 sense/ 5 0-
GGTCAGCCAACTCGTCACAG-30 antisense; osteopontin: 348 bp,
5 0-CCAAGTAAGTCCAACGAAAG-3 0 sense/5 0-GGTGATGTCCT
CGTCTGTA-3 0 antisense; type I collagen: 219 bp, 5 0-ATGTCTAGG
GTCTAGACATGTTCA-30 sense/5 0-CCTTGCCGTTGTCGCAGAC
G-3 0 antisense.
2.6. Assay of alkaline phosphatase activity
ALP activity was evaluated using the Sigma Diagnostics Alkaline
Phosphatase kits (Sigma-Aldrich) intended for the histochemical semi-
quantitative demonstration (procedure No. 85), according to the man-
ufacturers instructions.
2.7. Reversibility of MG-63 eﬀects
MG-63 cells were treated with 3-AB and after 48 h the medium was
removed and cells were washed and refed with fresh control medium
without 3-AB. After an additional 24, 48 or 72 h following the removal
of 3-AB, cytometry, Western blotting and RT/PCR analysis were
performed.Fig. 1. Pattern of ADP-ribosylation in either whole cells lysates or
nuclear extracts of MG-63 cells. Eﬀects of 3-AB. The cells were
incubated in the absence or presence of 3-AB, after which whole cell
lysates (60 lg) or nuclear extracts (30 lg) were resolved by 10% (A) or
12% (B, C) SDS–PAGE and immunoblotted with antibodies to either
poly-ADP-ribose (A and C), or H2b histone (B). Data are represen-
tatives of four separate experiments.3. Results
3.1. Pattern of ADP-ribosylation in MG-63 cell extracts.
Inhibitory eﬀects of 3-AB
Our initial goal in this study was to ascertain whether the
treatment with 3-AB of human osteosarcoma MG-63 cells re-
sults in a decrease in the content of ADP ribosylated proteins.
The analysis was performed by Western blot of whole cell ex-
tracts prepared after treatment with 3-AB. Probing the ﬁlter
with anti-PAR, a monoclonal antibody which recognizes
poly(ADP-ribose)-modiﬁed proteins and which does notcross-react with RNA, DNA or ADP-ribose monomers, a vast
array of poly(ADP-ribosyl)ated proteins appeared which sig-
niﬁcantly decreased with the time of the 3-AB treatment
(Fig. 1A). When nuclear extracts were probed with either
anti-H2B histone antibody (Fig. 1B) or anti-PAR antibody
(Fig. 1C), the results suggested that histones may be among
the poly(ADP-ribosyl)ated proteins which appeared to signiﬁ-
cantly decrease with 3-AB treatment.
3.2. 3-AB treatment induces morphological diﬀerentiation and
G1 phase arrest
The microscopy observation of MG-63 cells demonstrates
the changes induced, as compared with the control (Fig. 2A),
after 48 h of treatment with 3-AB (Fig. 2B). The potent reduc-
tion in cell number, accompanied by dramatic morphological
changes, is suggestive of diﬀerentiative attempts. Treated cells
appeared much larger than control, with a stellate morphol-
ogy, resembling osteocyte-bearing long cytoplasmatic protru-
sions which interconnect each other. Cytometry analysis
(Fig. 2C) conﬁrms [8] that 3-AB treatment induces potent
changes in the cell cycle phases population with G1 arrest.
The eﬀect of 3-AB was time-dependent with the percentage
of cells in G1 phase increasing by 8%, 18.4% and 24.4% after
16, 24 and 48 h of treatment, respectively. The analysis also
shows that the progressive G1 accumulation observed after
3-AB treatment was mostly associated with a concomitant de-
crease of cells in the S and G2-M phases of the cell cycle.
3.3. Rb inMG-63 cells is inactivated by hyperphosphorylation;
3-AB treatment induces the production of the
hypophosphorylated/active status of Rb and increases the
levels of the pRb/E2F complex
It is known that the G1 arrest of the cells depends on the
functional hypophosphorylated/active Rb form (pRb); pro-
gressive Rb phosphorylation leads to hyperphosphorylated/
inactive Rb form (ppRb) and simultaneous G1-S transition.
Hypophosphorylated Rb binds and sequesters cellular pro-
teins, most notably transcription factors of the E2F/DP family,
thereby regulating the transcription of genes [10]. We thus ex-
plored the functional status of Rb and the formation of pRb/
E2F complexes. Western blot analysis of whole cell lysates
probing the ﬁlter with antibody to the Rb (A/B pocket) (Fig.
Fig. 2. Microscopy and cytometry analysis of MG-63 cells treated
with 3-AB. The cells were treated for 48 h with vehicle (A) or with 3-
AB (B) and observed by phase contrast microscopy. Data are
representatives of seven separate experiments done in triplicate.
Magniﬁcation ·400. In panel C, the cells were analyzed by DNA ﬂow
cytometry. Data are representatives of four separate experiments.
Fig. 3. Eﬀects of 3-AB on the phosphorylated status of Rb and on the
levels of pRb/E2F complex. The cells were treated with 3-AB and
whole cell lysates (60 lg) were subjected to 10% SDS–PAGE and
immunoblotting (A). Filters were probed with antibodies to Rb (a), or
phospho-Rb Ser-780 (b), Ser-795 (c), Ser-807/811 (d). The ﬁlter d was
stripped and reprobed with anti Rb antibody (e). In panel B, whole cell
lysates (60 lg) were resolved by 10% SDS–PAGE and immunoblotted
with anti-E2F1 (a) or anti-Rb (b) antibodies. In addition, nuclear
extracts (400 lg protein each) were immunoprecipitated with anti Rb
antibodies, resolved by 10% SDS–PAGE and blotted. The ﬁlter was
probed with anti-E2F1 (c), stripped and reprobed with anti Rb
antibody (d). Data are representatives of four separate experiments.
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approximately 110–116 kDa. The bands might represent diﬀer-
ent Rb phosphorylation forms, with the lower mobility bands
being more highly phosphorylated than the higher mobility
bands. 3-AB treatment induced a marked reduction in the lower
mobility bands with a simultaneous increase in the higher
mobility bands. Probing new ﬁlters with antibodies against
phospho-Rb serine-780 (Fig. 3A, b), phospho-Rb serine-795
(Fig. 3A, c) and phospho-Rb serine-807/811 (Fig. 3A, d) dem-
onstrated that Rb protein in MG-63 cells is constitutively
hyperphosphorylated and that 3-AB treatment strongly de-
creases the amount of ppRb. Within 16 h of the addition of
3-AB to the cell culture, there was little decrease in ppRb
(not shown). The eﬀect of 3-AB was progressively more evi-
dent after 24 h and 48 h of treatment and was evident on all
the phosphoserine residues studied, in particular on phospho-
serine 795. When the ﬁlter probed with anti-phospho-Rb ser-
ine-795 antibody was stripped and reprobed with the anti-Rb
antibody (Fig. 3A, e), it was evident that the lowering in the
ppRb form was accompanied by a concomitant increase in
the pRb form.
In light of these results, we then sought to determine whether
3-AB treatment induced changes in the pRb/E2F complex. Ini-
tially, nuclear extracts were submitted to Western blot analysis
and the ﬁlters were reacted with either anti E2F-1 (Fig. 3B, a)or anti-Rb (Fig. 3B, b) antibodies. The results show that 3-AB
treatment did not change the level of E2F-1, while it markedly
modiﬁed the level of ppRb in favor of pRb. Thereafter, the nu-
clear extracts were immunoprecipitated with anti-Rb antibody,
resolved by western blot and probed with the anti E2F-1 anti-
body (Fig. 3B, c). The results demonstrated that 3-AB treat-
ment induced a signiﬁcant increase in the E2F-1 component.
When the same ﬁlter was stripped and reprobed with the anti
Rb antibody (Fig. 3B, d), the results showed that, after 3-AB
treatment, most of the immunoprecipitated Rb is present in
the hypophosphorylated form. The ﬁndings suggest that 3-
AB treatment induces a signiﬁcant increase in the pRb/E2F
complex.
3.4. 3-AB treatment decreases the expression of genes involved in
cell cycle progression and increases that of genes responsible
for osteoblast diﬀerentiation program
pRb phosphorylation occurs by cyclin-dependent kinases
(CDKs), with cyclin D1 playing crucial roles in favoring the
progression from G1 into the S phase which, in turn, is im-
peded by p21/Waf1, a potent inhibitor of CDKs [11].
We thus ascertained whether treatment with 3-AB induces
changes in the levels of these cell cycle regulators byWestern blot
(Fig. 4A) and RT-PCR (Fig. 4B) analysis of whole cell lysates.
The Figure demonstrates that the level of cyclin D1 was quite
high, while p21/Waf-1 was barely measurable. Treatment with
3-AB induced a considerable time-dependent decrease in the
Fig. 4. Eﬀects of 3-AB on the expression of both various typical controllers of cell cycle and various markers of osteoblast diﬀerentiation. (A), equal
amounts of whole cell lysates (60 lg) were subjected to SDS–PAGE and immunoblotting. Filters were probed with antibodies to cyclin D1, p21/
Waf1, b-catenin, c-jun, ID2, c-Myc, osteopontin (OSP), N-cadherin (N-CAD), osteocalcin (OSC), and type I collagen. The data shown under each
blot are from the densitometry analysis. (B), RNA was extracted and analyzed by RT-PCR with primers for alkaline phosphatase (ALP), cyclin D1,
c-Jun, b-catenin, ID2, c-Myc, type I collagen (coll), OPN, OSC or GAPDH (internal control). (C), hystochemical evaluation of ALP. Data are
representatives of ﬁve separate experiments.
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The results suggest that 3-AB induces molecular changes that
can inhibitG1/S transition. Since it is known that cyclinD1 tran-
scription can be regulated byb-catenin, we examined its level. As
Fig. 4 shows,MG-63 cells express high levels of b-catenin which
potently decrease by 3-AB-treatment. Also, c-Jun (a gene in-
volved in cell immortalization in a number of cancer cells) can
be regulated by b-catenin and the ﬁgure shows signiﬁcant levels
of c-Jun that markedly lowered after 3-AB-treatment.
To explore whether additional mechanisms can contribute to
the functional inactivation of pRb, we examined the expression
of the helix-loop-helix ID2 proteins, known to be involved in
the disturbed regulation of cell cycle by interfering with Rb
protein [12]. Western blot and RT-PCR analysis (Fig. 4) dem-
onstrated very high levels of ID2, which markedly decreased
after 3-AB treatment. Since ID2 operates, at least in part, un-
der the control of c-Myc [13], which, by raising ID2 levels, cir-
cumvent the block on cell cycle progression imposed by the Rb
pathway, we also checked for c-Myc involvement. The results
demonstrate that MG-63 cells even express signiﬁcant levels of
c-Myc, which were downregulated after 3-AB-treatment.
We have previously shown [8] that in MG-63 cells, 3-AB
treatment induces morphological and biochemical changes
suggestive of osteocyte diﬀerentiation. Of the biochemical pat-tern previously analyzed [8], we have shown that CD44 (the
osteopontin receptor, sensitive marker of osteocyte diﬀerentia-
tion) potently increases after 3-AB-treatment. Fig. 4 also dem-
onstrates that 3-AB treatment potently increases the
expression of ECM proteins and that of cell–cell adhesion pro-
teins which are implicated in the expression of the diﬀerentia-
tion bone-program. Western blot (A) and RT-PCR (B)
analysis show that 48 h of 3-AB-treatment signiﬁcantly in-
creases the expression of both osteopontin (5.1 fold), one of
the most prominent extracellular matrix proteins synthesized
by osteoblastic cells during bone development [14], and type
I collagen (3.2 fold), another major organic component of
bone ECM, which is fundamental to the development expres-
sion of the bone cell phenotype. Analysis of osteocalcin expres-
sion showed a 3.8-fold-increase that further conﬁrmed the
osteogenic phenotype induced by 3-AB treatment. Cell–cell
adhesion mediated by N-cadherins plays an essential role in
the control of human osteoblast diﬀerentiation and bone for-
mation [15], and Fig. 4A shows that after 3-AB treatment N-
cadherins increased by 2.2-fold. Interestingly, RT/PCR (Fig.
4B) and histochemical semiquantitative dosage (Fig. 4C) show
that prolonged times of 3-AB treatment (216 h) even stimu-
lated the expression of alkaline phosphatase, the most typical
marker of osteocyte diﬀerentiation.
Fig. 5. Reversibility of 3-AB eﬀects. Cytometry analysis of cell cycle
(A) and expression of cyclin D1 (B), after refeding in the absence of 3-
AB. Data are representatives of three separate experiments.
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cyclin D1analysis
In some experiments MG-63 cells were treated with 3-AB
and after 48 h, the medium was removed and cells were washed
and refed with fresh control medium without 3-AB. After an
additional 24, 48, or 72 h following the removal of 3-AB, cells
were analyzed either by cytometry for cell cycle (Fig. 5A), or
(after protein and RNA extraction) by Western blot and RT/
PCR for cyclin D1 (Fig. 5B). The results show that the eﬀect
induced by 48 h of 3-AB-treatment seemed not to be irrevers-
ible as it was entirely reversed after 78 h of refeding.4. Discussion
This paper describes the molecular mechanism by which
treatment with 3-AB, an inhibitor of PARP, allows human
osteosarcoma MG-63 cells to restrict growth and enter diﬀer-
entiation. We provide evidence that Rb protein, the main
brake on progress around the cell-division cycle, is constitu-
tively inactivated by hyperphosphorylation. As a consequence,
cells progress uncontrolled through the cell-cycle. The ﬁndings
show that 3-AB treatment potently reduced ADP-ribosylation
of nuclear proteins, among which the histones. The reduction
in ADP-ribosylation was accompanied by an accumulation of
the hypophosphorylated Rb form, with a simultaneous potent
downregulation of the gene products responsible for cell prolif-
eration (cyclin D1, b-catenin and c-Jun). This activated a cell-
cycle blockade mechanism which involved the p21/E2F system.
This paper also shows that MG-63 cells express very high lev-
els of Id2 proteins. These proteins are known to potently inhi-
bit diﬀerentiation in multiple cell types and to corroborate the
cell cycle machinery either by binding to the hypophosphory-
lated Rb protein and abolishing its growth-suppressing activity
[16] or by antagonizing the p21/Waf1 encoding gene [17].Treatment with 3-AB potently reduced ID2 expression and
this was accompanied by a potent increase in p21/WAF1 lev-
els. The treatment also induced downregulation of N-Myc,
known to upregulate ID2 gene [13]. Finally, treatment with
3-AB induced a signiﬁcant increase in the expression of osteo-
pontin, osteocalcin, type-1 collagen, N-cadherin and ALP, the
production of which is considered to be fundamental to the
developmental expression of the bone cell phenotype.
In conclusion, this paper suggests a scenario in which the
possible excessive ADP-ribosylation of nuclear proteins may
cause the aberrant gene expression that keeps Rb inactive
through hyperphosphorylation and MG-63 cells continuously
cycling. The cancellation of ADP-ribosylation of nuclear pro-
teins determined by 3-AB treatment may induce modulation in
chromatin structure, which in turn may result in gene expres-
sion reprogramming and the induction of diﬀerentiation.
Localized changes in chromatin structure are a key event in
the transcriptional regulation of genes. Histone tails are sub-
ject to multiple post-translational modiﬁcations such as acety-
lation, phosphorylation, ubiquitination, methylation, and
poly-ADP-ribosylation, which play a role in transcriptional
regulation [18]. It has been shown that PARP can modify nu-
clear proteins creating an anionic poly(ADP-ribose) matrix,
which promotes the remodeling of chromatin [2]. Further-
more, excessive PARP activity may be implicated in the path-
ogenesis of numerous clinical conditions including cancer [19].
PARP inhibitors have recently been shown to be eﬀective in
sensitizing cancer cells to drug-induced apoptosis, and treat-
ment of cancer with PARP inhibitors in combination with
other agents thus appears to be a promising new therapeutic
approach [20]. Osteosarcoma is a common malignant tumor
for which the current drug treatment is chemotherapy. This
commonly involves a combination of multiple anticancer
drugs, such as doxorubicin, cisplatin, and/or methotrexate.
However, more than 30% of patients are resistant to these che-
motherapy regimens [21]. To our knowledge, our paper is the
ﬁrst demonstration that treatment with 3-AB alone can induce
antiproliferative and diﬀerentiative eﬀects in cancer cells. We
propose that PARP inhibition may be a novel approach for
the treatment of osteosarcoma.
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